- Home
- CIK vs ALDX Comparison
CIK vs ALDX Comparison
Compare CIK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- ALDX
- Stock Information
- Founded
- CIK 1987
- ALDX 2004
- Country
- CIK United States
- ALDX United States
- Employees
- CIK N/A
- ALDX N/A
- Industry
- CIK Finance/Investors Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- ALDX Health Care
- Exchange
- CIK Nasdaq
- ALDX Nasdaq
- Market Cap
- CIK 154.6M
- ALDX 133.7M
- IPO Year
- CIK N/A
- ALDX 2014
- Fundamental
- Price
- CIK $2.85
- ALDX $2.15
- Analyst Decision
- CIK
- ALDX Strong Buy
- Analyst Count
- CIK 0
- ALDX 2
- Target Price
- CIK N/A
- ALDX $9.50
- AVG Volume (30 Days)
- CIK 115.4K
- ALDX 1.2M
- Earning Date
- CIK 01-01-0001
- ALDX 05-14-2025
- Dividend Yield
- CIK 9.03%
- ALDX N/A
- EPS Growth
- CIK N/A
- ALDX N/A
- EPS
- CIK N/A
- ALDX N/A
- Revenue
- CIK N/A
- ALDX N/A
- Revenue This Year
- CIK N/A
- ALDX N/A
- Revenue Next Year
- CIK N/A
- ALDX N/A
- P/E Ratio
- CIK N/A
- ALDX N/A
- Revenue Growth
- CIK N/A
- ALDX N/A
- 52 Week Low
- CIK $2.50
- ALDX $1.14
- 52 Week High
- CIK $3.19
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CIK 51.68
- ALDX 38.93
- Support Level
- CIK $2.81
- ALDX $2.15
- Resistance Level
- CIK $2.92
- ALDX $2.30
- Average True Range (ATR)
- CIK 0.04
- ALDX 0.15
- MACD
- CIK 0.00
- ALDX 0.06
- Stochastic Oscillator
- CIK 50.00
- ALDX 37.93
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.